Motley Fool Wealth Management LLC Buys 125,486 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Motley Fool Wealth Management LLC raised its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 83.9% during the 2nd quarter, Holdings Channel.com reports. The fund owned 275,082 shares of the biopharmaceutical company’s stock after purchasing an additional 125,486 shares during the quarter. Motley Fool Wealth Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $10,002,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of RARE. GAMMA Investing LLC lifted its stake in Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 323 shares during the period. Parallel Advisors LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 669 shares during the period. ANTIPODES PARTNERS Ltd bought a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth approximately $57,000. Headlands Technologies LLC bought a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth approximately $59,000. Finally, Covestor Ltd lifted its stake in shares of Ultragenyx Pharmaceutical by 86.8% in the 1st quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 795 shares during the period. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 5.3%

Ultragenyx Pharmaceutical stock opened at $35.31 on Tuesday. The firm has a 50 day moving average of $30.84 and a 200 day moving average of $32.95. The firm has a market capitalization of $3.40 billion, a price-to-earnings ratio of -6.39 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 12-month low of $25.81 and a 12-month high of $55.06.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. During the same period last year, the firm posted ($1.52) EPS. The company’s revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president directly owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This trade represents a 3.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Howard Horn sold 7,942 shares of the stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $31.51, for a total transaction of $250,252.42. Following the sale, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,456 shares of company stock valued at $328,486. Insiders own 5.50% of the company’s stock.

Analyst Upgrades and Downgrades

RARE has been the topic of several recent research reports. Wells Fargo & Company initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Monday, October 20th. They issued an “overweight” rating and a $65.00 price objective on the stock. Morgan Stanley lowered their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, July 14th. Canaccord Genuity Group lowered their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $105.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, September 5th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $82.27.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.